Green Therapeutic Biocapsules: Using Plant Cells to Orally Deliver Biopharmaceuticals

The use of innovative platforms to produce biopharmaceuticals cheaply and deliver them through noninvasive routes could expand their social benefits. Coverage should increase as a consequence of lower cost and higher patient compliance due to painless administration. For more than two decades of res...

Full description

Saved in:
Bibliographic Details
Published in:Trends in biotechnology (Regular ed.) 2018-10, Vol.36 (10), p.1054-1067
Main Authors: Rosales-Mendoza, Sergio, Nieto-Gómez, Ricardo
Format: Article
Language:English
Subjects:
Administration, Oral
Animal models
Antigens
Biological Products - administration & dosage
Biomass
Biopharmaceuticals
Candidates
cell wall
Clinical trials
Coverage
Diabetes
Disease
Drug Delivery Systems
E coli
Enzymes
Genetic engineering
glucocerebrosidase
Hemophilia
Humans
Immunoglobulins
immunotherapy
low-cost therapies
oral delivery
Plant cells
Plant Cells - metabolism
plant-based vaccines
Plants (botany)
Plants, Genetically Modified - metabolism
Tobacco
Tropical diseases
Vaccines
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The use of innovative platforms to produce biopharmaceuticals cheaply and deliver them through noninvasive routes could expand their social benefits. Coverage should increase as a consequence of lower cost and higher patient compliance due to painless administration. For more than two decades of research, oral therapies that rely on genetically engineered plants for the production of biopharmaceuticals have been explored to treat or prevent high-impact diseases. Recent reports on the successful oral delivery of plant-made biopharmaceuticals raise new hopes for the field. Several candidates have shown protection in animal models, and efforts to establish their production on an industrial scale are ongoing. These advances and perspectives for the field are analyzed. Plant-made biopharmaceuticals have been researched for more than two decades, but such medicines are not yet commercially available. Recent advances have improved the oral delivery potential of plant-made biopharmaceuticals. Oral delivery of biopharmaceuticals using the B subunit of cholera toxin as a transmucosal carrier has brought new hope to this field. The development of oral plant-based vaccines still requires addressing some regulatory and technical aspects.
ISSN:0167-7799
1879-3096
DOI:10.1016/j.tibtech.2018.05.010